News & Publications

our latest breakthroughs

Our platform, which combines oncRNA technology with AI, provides actionable insights into cancer biology.

Featured

Exai Bio’s RNA-based Liquid Biopsy Platform Delivers Promising Data on Detecting Breast Cancer at its Earliest Stages

Read More >

News & Press

follow us
‍into the future.

Exai Bio Presents Data Further Validating its Liquid Biopsy Platform at the 2023 World Conference on Lung Cancer

Sep 2023

Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Jun 2023

Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting

Apr 2023

Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai’s Novel RNA-based Liquid Biopsy Platform in Breast Cancer

Mar 2023

Exai Bio Announces Appointments of Emi Zychlinsky and Seema Singh Bhan to its Executive Leadership Team

Feb 2023

Exai Bio’s RNA-based Liquid Biopsy Platform Delivers Promising Data on Detecting Breast Cancer at its Earliest Stages

Dec 2022

Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer

Sep 2022
Pat Arensdorf sits down with CLP to discuss how our technology fits into and improves the diagnostic continuum.

How oncRNA Technology Could Revolutionize Cancer Diagnostics

Sep 2022
Exai Bio is working to develop blood-based tests for cancer early detection and potentially other applications, enabled by genome-wide analysis of small noncoding RNAs.

Exai Bio Commercializing Noncoding RNA Method for Liquid Biopsy Applications

Apr 2022
Exai Bio is presenting data from its scientific research program on the discovery and validation of tumor-specific, orphan non-coding RNAs.

Exai Bio Demonstrates its Unique RNA-based Liquid Biopsy Strategy for Early Detection and Monitoring of Multiple Cancers

Apr 2022
Exai Bio announced it has raised a $67.5 million Series A financing to accelerate development of its non-invasive, RNA-based liquid biopsy platform.

Exai Bio Secures $67.5 Million Series A

Dec 2021

Publications & Presentations

science driven, patient focused.

WCLC 2023

AI-Based Early Detection and Subtyping of Non-Small Cell Lung Cancer from Blood Samples Using Orphan Non-Coding RNAs

Sep 2023
ASCO 2023

Detection of early-stage cancers using circulating orphan non-coding RNAs in blood

Jun 2023
BOG 2023

Transcriptome-wide co-expression of small non-coding RNAs and genes in cancer

May 2023
AACR 2023

Blood-based Early Detection of Non-small cell Lung Cancer using Orphan Noncoding RNAs

Apr 2023
SABCS 2022

Early Stage Breast Cancer Detection using Orphan Non-coding RNAs

Dec 2022
ESMO 2022

Serum-Based Colorectal Cancer Detection using OncRNAs

Sep 2022
AACR 2022

Discovery and Validation of Orphan Noncoding RNA Profiles across Multiple Cancers in TCGA and Two Independent Cohorts

Apr 2022
SABCS 2021

Tumor-Released Circulating Orphan Noncoding RNAs Reflect Treatment Response and Survival in Breast Cancer

Dec 2021
Nature Medicine

Cancer Cells Exploit an Orphan RNA to Drive Metastatic Progression

Nov 2018

Keep Reading

No further publications found.
>

interested in collaborating?
reach out to us.

contact us
Close the cookie popup
Cookie Settings
By clicking "Accept All", you are agreeing to store cookies on your device to enhance your experience and help Exai's marketing.
Accept All
cookie settings
Close the cookie popup
Cookie Settings
By clicking "Accept All", you are agreeing to store cookies on your device to enhance your experience and help Exai's marketing. More info.
Strictly Necessary
Required in order to enable all basic site functionality.
Accept All
save settings